AUG 1 6 2004 W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Burkhard Jaeger et al) Art Unit: 1625

U.S. Appln. No. : 10/727,225) Examiner: To be assigned

Confirmation No.: 5189

U.S. Filing Date: December 3, 2003

Title of Invention: PROCESS FOR PREPARING OPTICALLY ACTIVE

DIHYDROPYRONES

Attny. Docket No.: 1/1433

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

August 12, 2004

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:
Fransmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.
1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.
1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:
A statement as specified in 37 C.F.R. §1.97(e) [see below]; or
The fee set forth in 37 C.F.R. §1.17(p).

	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
\$1.97(c)	1.97(d). This Statement is being filed after the period specified in 37 C.F.R. but on or before payment of the issue fee. This Statement is accompanied by a state as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
1.	.97(e).
C	Each item of information contained in the instant information disclosure tatement was first cited in any communication from a foreign patent office in a ounterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or
fe m ii §	No item of information contained in the instant information disclosure tatement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after naking reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.
	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
disclosu counterp in sectio	1.704(d). Each item of information contained in the accompanying information re statement was cited in a communication from a foreign patent office in a part application, which communication was not received by any individual designated on 1.56(c) more than thirty (30) days prior to the filing of the accompanying tion disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfally submitted,

Alan R. Stempel

Attorney for Applicant(s)

Reg. No. 28,991

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4868 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on August 12, 20,04.

Alan R. Stempel, Reg. No/2

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| Approved for use through 07/31/2006. OMB 0651-0031
| U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
| Approved for use through 07/31/2006. OMB 0651-0031
| U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
| Approved for use through 07/31/2006. OMB 0651-0031
| U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
| Approved for use through 07/31/2006. OMB 0651-0031
| U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
| Approved for use through 07/31/2006. OMB 0651-0031
| U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
| U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
| U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
| U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
| U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
| U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
| U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
| U.S. Patent and U

Substitute for form 1449A/PTO

US-US-ŪS-US-ŪS-US-

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/727,225 Filing Date December 3, 2003 First Named Inventor **Burkhard Jaeger** Art Unit 1625 **Examiner Name** To be assigned Attorney Docket Number 1/1433

(Use as many sheets as necessary) 2 Sheet S. PATENT DOCUMENTS Pages, Columns, Lines, Where Name of Patentee or Examiner Cite No.1 **Document Number Publication Date** MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Initials* Figures Appear Number-Kind Code^{2 (If known)} ^{US-}2002/0161037 A1 10/31/2002 Oliver Meyer et al US. US IIS. US-บร-US-ับร-US-US-US-ŪS-

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ 'Number ⁴ 'Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵			
		DE 10108471 C1	11/21/2002	BI Pharma KG					
***************************************		WO 9819997	05/14/1998	Warner-Lambert Co.	***************************************	L			
•••••					***************************************				

***************************************	1					<u></u>			

	·		
Euroinan		Date	
Examiner			
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

The same of the sa AUG 1 6 2004 PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it excludes a collection of information unless it ex

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

_	-150							
DESABARULE for form 1449B/PTO					Complete if Known			
					Application Number	10/727,225		
	INFO	RMATION DI	SCLO	SURE	Filing Date	December 3, 2003		
STATEMENT BY APPLICANT				CANT	First Named Inventor	Burkhard Jaeger		
					Art Unit	1625		
		(Use as many sheets as	necessary)	Examiner Name	To be assigned		
	Sheet	2	of	2	Attorney Docket Number	1/1433		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
		STEVE R. TURNER ET AL; Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class; J. Med. Chem. (1998) Vol. 41 pages 3467-3476; American Chemical Society				
		Copy of International Search Report Reference #PCT/EP 03/13851				
	•••••					
······································						

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in contominate and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.